Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. Usmani Discusses Immunotherapy in Hematologic Malignancies

June 12th 2018

Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses immunotherapy in hematologic malignancies.

Dr. Hilal Discusses Rituximab Maintenance in Mantle Cell Lymphoma

June 8th 2018

Talal Hilal, MB, BCh, assistant professor of medicine, Mayo Clinic, discusses the meta-analysis of rituximab maintenance for patients with mantle cell lymphoma.

Ibrutinib/Buparlisib Reaches Response in Half of NHL Cohort

June 7th 2018

Combining the BTK inhibitor ibrutinib (Imbruvica) with the PI3K inhibitor buparlisib induced an objective response in 18 of 37 patients with relapsed/refractory non-Hodgkin lymphoma.

ASCO Studies Refine CAR T Cell Use

June 7th 2018

Several studies presented at the 2018 ASCO Annual Meeting helped further refine and inform treatment strategies for the budding class of CAR T-cell therapies, with a focus on predicting adverse events and optimizing efficacy.

Dr. Ghosh on the Role of Bleomycin in Hodgkin Lymphoma

June 6th 2018

Nilanjan Ghosh, MD, PhD, physician, Levine Cancer Institute, discusses the role of bleomycin in the treatment of patients with classical Hodgkin lymphoma.

Ivosidenib Demonstrates Durable Responses in R/R AML

June 5th 2018

Ivosidenib induced an overall response rate of 41.6% (95% CI, 32.9-50.8) in patients with IDH1-positive relapsed/refractory acute myeloid leukemia.

CD22 Immunotoxin Achieves Durable Complete Remissions in Relapsed Hairy Cell Leukemia

June 4th 2018

Moxetumomab pasudotox, a first-in-class recombinant immunotoxin targeting CD22, produced deep and durable responses in a substantial proportion of pretreated patients with relapsed/refractory hairy cell leukemia.

Anti-CD47 Antibody Plus Rituximab Demonstrates Efficacy in Half of Patients With Relapsed/Refractory NHL

June 4th 2018

Half of a small group of patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL) had major responses to treatment with an anti-CD47 antibody plus rituximab (Rituxan).

FDA Grants Frontline Eltrombopag Priority Review for Severe Aplastic Anemia

May 31st 2018

The FDA has granted a priority review to a supplemental new drug application for eltrombopag (Promacta) for use in combination with standard immunosuppressive therapy as a frontline treatment for patients with severe aplastic anemia.

ASCO 2018: Top Oncologists Select Key, Practice-Changing Abstracts

May 30th 2018

Key opinion leaders spoke with OncLive ahead of the 2018 ASCO Annual Meeting to share the top abstracts they believe could have the greatest impact on clinical practice and patient outcomes across lymphomas, gastrointestinal cancers, genitourinary cancers, and lung cancer.

FDA Grants Crizotinib Breakthrough Designation for MET+ NSCLC and ALK+ ALCL

May 30th 2018

The FDA has granted crizotinib a breakthrough therapy designation for the treatment of patients with metastatic non–small cell lung cancer with MET exon 14 alterations, and for use in patients with relapsed/refractory ALK+ anaplastic large cell lymphoma.

FDA Grants Priority Review to Gilteritinib for FLT3+ AML

May 29th 2018

The FDA has granted a priority review to a new drug application for gilteritinib for the treatment of adult patients with FLT3 mutation–positive relapsed or refractory acute myeloid leukemia.

Novel Agents Change the Treatment of Acute Lymphoblastic Leukemia

May 29th 2018

A panel of experts discuss the latest data on several novel agents for ALL and provided insights on how to align these treatments in challenging settings.

Harvard Expert Sees Potential in BCL-2 Combos

May 27th 2018

Anthony G. Letai, MD, PhD, discusses the complex nature of apoptosis and efforts to target the process.

Dr. Snyder Discusses Emerging Agents in Myelofibrosis

May 25th 2018

David S. Snyder, MD, associate chair and professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, discusses emerging agents in myelofibrosis.

Dr. Htut on Immunotherapy in Multiple Myeloma

May 25th 2018

Maung Myo Htut, MD, assistant clinical professor of hematology and hematopoietic cell transplantation, City of Hope, discusses the use of immunotherapy in the treatment of patients with multiple myeloma.

Ofatumumab Combo Falls Short in Indolent Non-Hodgkin Lymphoma

May 25th 2018

Adding ofatumumab (Arzerra) to bendamustine (Treanda) failed to improve progression-free survival in patients with indolent B-cell non-Hodgkin lymphoma who did not respond to rituximab (Rituxan) monotherapy.

New Strategies Aim at Survival Protein MCL-1

May 24th 2018

Myeloid cell leukemia 1 has emerged as an intriguing target for anticancer drug development as researchers turn their attention to strategies directed at evasion of apoptosis.

Expert Addresses Advances and Challenges in MDS

May 24th 2018

Jing Ai, MD, discusses the treatment of patients with myelodysplastic syndrome.

Expert Weighs Treatment Methods in Hodgkin Lymphoma

May 22nd 2018

Nilanjan Ghosh, MD, PhD, discusses the advances and ongoing research in frontline treatment of patients with Hodgkin lymphoma.